|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SAMD9L |
Gene summary for SAMD9L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SAMD9L | Gene ID | 219285 |
| Gene name | sterile alpha motif domain containing 9 like | |
| Gene Alias | ATXPC | |
| Cytomap | 7q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IVG5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 219285 | SAMD9L | C04 | Human | Oral cavity | OSCC | 1.86e-09 | 5.32e-01 | 0.2633 |
| 219285 | SAMD9L | C21 | Human | Oral cavity | OSCC | 8.08e-30 | 1.08e+00 | 0.2678 |
| 219285 | SAMD9L | C30 | Human | Oral cavity | OSCC | 4.25e-16 | 8.40e-01 | 0.3055 |
| 219285 | SAMD9L | C46 | Human | Oral cavity | OSCC | 1.42e-10 | 3.91e-01 | 0.1673 |
| 219285 | SAMD9L | C08 | Human | Oral cavity | OSCC | 3.22e-10 | 4.06e-01 | 0.1919 |
| 219285 | SAMD9L | LN46 | Human | Oral cavity | OSCC | 6.35e-14 | 7.13e-01 | 0.1666 |
| 219285 | SAMD9L | EOLP-1 | Human | Oral cavity | EOLP | 2.88e-03 | 1.65e-01 | -0.0202 |
| 219285 | SAMD9L | SYSMH2 | Human | Oral cavity | OSCC | 1.01e-14 | 3.67e-01 | 0.2326 |
| 219285 | SAMD9L | SYSMH3 | Human | Oral cavity | OSCC | 1.04e-11 | 3.37e-01 | 0.2442 |
| 219285 | SAMD9L | SYSMH6 | Human | Oral cavity | OSCC | 2.02e-02 | 2.30e-01 | 0.1275 |
| 219285 | SAMD9L | male-WTA | Human | Thyroid | PTC | 3.56e-07 | 1.36e-01 | 0.1037 |
| 219285 | SAMD9L | PTC01 | Human | Thyroid | PTC | 2.97e-10 | 1.35e-01 | 0.1899 |
| 219285 | SAMD9L | PTC04 | Human | Thyroid | PTC | 9.39e-04 | 1.06e-01 | 0.1927 |
| 219285 | SAMD9L | PTC05 | Human | Thyroid | PTC | 1.82e-11 | 4.89e-01 | 0.2065 |
| 219285 | SAMD9L | PTC06 | Human | Thyroid | PTC | 2.14e-14 | 4.45e-01 | 0.2057 |
| 219285 | SAMD9L | PTC07 | Human | Thyroid | PTC | 6.10e-17 | 2.89e-01 | 0.2044 |
| 219285 | SAMD9L | ATC09 | Human | Thyroid | ATC | 4.36e-05 | 4.30e-01 | 0.2871 |
| 219285 | SAMD9L | ATC11 | Human | Thyroid | ATC | 1.85e-02 | 4.19e-01 | 0.3386 |
| 219285 | SAMD9L | ATC12 | Human | Thyroid | ATC | 1.55e-13 | 3.93e-01 | 0.34 |
| 219285 | SAMD9L | ATC13 | Human | Thyroid | ATC | 5.16e-36 | 7.02e-01 | 0.34 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SAMD9L | SNV | Missense_Mutation | c.988N>C | p.Asp330His | p.D330H | Q8IVG5 | protein_coding | deleterious(0.04) | benign(0.386) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| SAMD9L | SNV | Missense_Mutation | novel | c.801N>C | p.Met267Ile | p.M267I | Q8IVG5 | protein_coding | tolerated(0.39) | probably_damaging(0.91) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SAMD9L | SNV | Missense_Mutation | c.3230G>T | p.Arg1077Leu | p.R1077L | Q8IVG5 | protein_coding | deleterious(0) | possibly_damaging(0.706) | TCGA-A2-A0SU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SAMD9L | SNV | Missense_Mutation | c.1432N>G | p.Thr478Ala | p.T478A | Q8IVG5 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| SAMD9L | SNV | Missense_Mutation | c.358N>C | p.Asp120His | p.D120H | Q8IVG5 | protein_coding | tolerated(0.12) | possibly_damaging(0.464) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SAMD9L | SNV | Missense_Mutation | c.963N>G | p.Phe321Leu | p.F321L | Q8IVG5 | protein_coding | deleterious(0) | benign(0.11) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SAMD9L | SNV | Missense_Mutation | c.2872N>C | p.Glu958Gln | p.E958Q | Q8IVG5 | protein_coding | deleterious(0.01) | possibly_damaging(0.488) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SAMD9L | SNV | Missense_Mutation | c.1948N>C | p.Glu650Gln | p.E650Q | Q8IVG5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SAMD9L | SNV | Missense_Mutation | rs746980471 | c.853C>T | p.Arg285Trp | p.R285W | Q8IVG5 | protein_coding | deleterious(0) | benign(0.047) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SAMD9L | SNV | Missense_Mutation | novel | c.2221N>T | p.His741Tyr | p.H741Y | Q8IVG5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |